Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02860286
Title Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

malignant mesothelioma

Therapies

Tazemetostat

Age Groups: senior | adult
Covered Countries USA | FRA


No variant requirements are available.